Expertise in
12
conditions

Kilian Eyerich

Hugstetter Str. 55, 
Freiburg, BW, DE 
Expertise in
12
conditions
Hugstetter Str. 55, 
Freiburg, BW, DE 

Overview

Kilian Eyerich practices practicing medicine in Freiburg, Germany.

Mr. Eyerich is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Atopic Dermatitis, Psoriasis, Plaque Psoriasis, and Nummular Eczema.

He is actively involved in clinical research, co-authoring 239 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Baricitinib, Corticosteroid
Study Phase: Phase 3
An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 2
View 1 Less Clinical Trial

239 Total Publications

Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
Benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the Heads Up trial.
Journal: The Journal of dermatological treatment
Published: June 01, 2026

Frequently Asked Questions about Kilian Eyerich

Is Kilian Eyerich a top-rated expert for Atopic Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Kilian Eyerich is classified as an Elite expert for Atopic Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kilian Eyerich participate in research or clinical trials?

Yes. Kilian Eyerich has published 239 articles and abstracts on conditions like Atopic Dermatitis. You can view a list of Kilian Eyerich's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eyerich's expertise for a condition
ConditionClose
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile